TimesSquare Capital Management LLC Sells 14,442 Shares of Xenon Pharmaceuticals Inc. $XENE

TimesSquare Capital Management LLC cut its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 2.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 556,800 shares of the biopharmaceutical company’s stock after selling 14,442 shares during the quarter. TimesSquare Capital Management LLC owned 0.72% of Xenon Pharmaceuticals worth $22,356,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of the stock. Elevation Point Wealth Partners LLC purchased a new stake in Xenon Pharmaceuticals in the 2nd quarter valued at $32,000. Osaic Holdings Inc. grew its stake in shares of Xenon Pharmaceuticals by 541.4% in the 2nd quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 1,034 shares in the last quarter. L1 Capital Pty Ltd purchased a new stake in shares of Xenon Pharmaceuticals in the second quarter valued at about $41,000. State of Wyoming raised its holdings in shares of Xenon Pharmaceuticals by 112.8% in the third quarter. State of Wyoming now owns 1,151 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 610 shares during the last quarter. Finally, Amalgamated Bank bought a new position in shares of Xenon Pharmaceuticals during the second quarter valued at about $81,000. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Price Performance

Shares of NASDAQ XENE opened at $41.48 on Monday. The stock has a market capitalization of $3.21 billion, a PE ratio of -10.66 and a beta of 0.96. Xenon Pharmaceuticals Inc. has a one year low of $26.74 and a one year high of $46.60. The business’s fifty day moving average price is $42.59 and its 200-day moving average price is $40.41.

Insiders Place Their Bets

In other news, CEO Ian Mortimer sold 40,000 shares of the business’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $44.43, for a total value of $1,777,200.00. Following the sale, the chief executive officer owned 6,000 shares of the company’s stock, valued at $266,580. The trade was a 86.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have sold a total of 65,302 shares of company stock worth $2,924,128 in the last three months. 4.07% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

XENE has been the subject of several analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research note on Friday, January 9th. Needham & Company LLC reaffirmed a “buy” rating and issued a $55.00 target price on shares of Xenon Pharmaceuticals in a report on Tuesday, November 4th. Wells Fargo & Company lifted their price target on Xenon Pharmaceuticals from $44.00 to $48.00 and gave the stock an “overweight” rating in a report on Thursday, December 11th. JPMorgan Chase & Co. boosted their price objective on Xenon Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a research report on Friday, January 9th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $55.00 target price on shares of Xenon Pharmaceuticals in a research report on Tuesday, November 4th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $54.73.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.